ArticleMethods in molecular biology (Clifton, N.J.)2025
A Synthetic Nanoparticle to Mimic High-Density Lipoprotein for Reverse Cholesterol Transport.
Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis is attributed to one of the highest mortality rates in the United States and many other countries. Hypercholesterolemia is a significant risk factor for atherosclerosis. The balance between high-density lipoprotein (HDL) and low-density lipoprotein maintains the cholesterol levels by removing or depositing it, respectively. By synthesizing HDL-mimicking nanoparticles (NPs), the therapeutic removal of cholesterol may be plausible upon administration. In addition, HDL has been known to be an excellent transporter of various cargos. The manipulations of such characteristics could yield NPs that can target atherosclerotic plaque sites. To investigate this possibility, we developed HDL-mimicking NPs using FDA-approved polymers. This NP can participate in cholesterol efflux, possibly through a reverse cholesterol transport pathway.
Indexed as
Identifiers
40498205What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.